283 related articles for article (PubMed ID: 26700862)
1. Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner.
Chen C; Lu M; Pan Q; Fichna J; Zheng L; Wang K; Yu Z; Li Y; Li K; Song A; Liu Z; Song Z; Kreis M
PLoS One; 2015; 10(12):e0145556. PubMed ID: 26700862
[TBL] [Abstract][Full Text] [Related]
2. Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome.
Zielińska M; Jarmuż A; Wasilewski A; Cami-Kobeci G; Husbands S; Fichna J
Pharmacol Rep; 2017 Apr; 69(2):350-357. PubMed ID: 28187396
[TBL] [Abstract][Full Text] [Related]
3. Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.
Zielińska M; Jarmuż A; Sałaga M; Lipkowski AW; Fichna J
Pharmacol Rep; 2016 Feb; 68(1):32-6. PubMed ID: 26721348
[TBL] [Abstract][Full Text] [Related]
4. Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome.
Zielińska M; Chen C; Mokrowiecka A; Cygankiewicz AI; Zakrzewski PK; Sałaga M; Małecka-Panas E; Wlaź P; Krajewska WM; Fichna J
J Pharm Pharmacol; 2015 Feb; 67(2):244-54. PubMed ID: 25515402
[TBL] [Abstract][Full Text] [Related]
5. Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.
Sobczak M; Cami-Kobeci G; Sałaga M; Husbands SM; Fichna J
Eur J Pharmacol; 2014 Aug; 736():63-9. PubMed ID: 24815321
[TBL] [Abstract][Full Text] [Related]
6. Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea-predominant IBS.
Fichna J; Sobczak M; Mokrowiecka A; Cygankiewicz AI; Zakrzewski PK; Cenac N; Sałaga M; Timmermans JP; Vergnolle N; Małecka-Panas E; Krajewska WM; Storr M
Neurogastroenterol Motil; 2014 Nov; 26(11):1539-50. PubMed ID: 25041572
[TBL] [Abstract][Full Text] [Related]
7. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
8. Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
Sałaga M; Polepally PR; Sobczak M; Grzywacz D; Kamysz W; Sibaev A; Storr M; Do Rego JC; Zjawiony JK; Fichna J
J Pharmacol Exp Ther; 2014 Jul; 350(1):69-78. PubMed ID: 24891526
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive Effect of Ghrelin in a Rat Model of Irritable Bowel Syndrome Involves TRPV1/Opioid Systems.
Mao Y; Li Z; Chen K; Yu H; Zhang S; Jiang M; Ma Y; Liang C; Liu H; Li H; Hua Q; Zhou H; Sun Y; Fan X
Cell Physiol Biochem; 2017; 43(2):518-530. PubMed ID: 28930716
[TBL] [Abstract][Full Text] [Related]
10. Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats.
Yu ZC; Cen YX; Wu BH; Wei C; Xiong F; Li DF; Liu TT; Luo MH; Guo LL; Li YX; Wang LS; Wang JY; Yao J
World J Gastroenterol; 2019 Aug; 25(29):3956-3971. PubMed ID: 31413530
[TBL] [Abstract][Full Text] [Related]
11. Chitin-glucan improves important pathophysiological features of irritable bowel syndrome.
Valibouze C; Dubuquoy C; Chavatte P; Genin M; Maquet V; Modica S; Desreumaux P; Rousseaux C
World J Gastroenterol; 2024 Apr; 30(16):2258-2271. PubMed ID: 38690023
[TBL] [Abstract][Full Text] [Related]
12. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
Scarpellini E; Laterza L; Ianiro G; Tack J; Abenavoli L; Gasbarrini A
Expert Opin Pharmacother; 2016 Jul; 17(10):1395-402. PubMed ID: 27267380
[TBL] [Abstract][Full Text] [Related]
13. Antinociceptive and antidiarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: role of nitric oxide.
Paragomi P; Rahimian R; Kazemi MH; Gharedaghi MH; Khalifeh-Soltani A; Azary S; Javidan AN; Moradi K; Sakuma S; Dehpour AR
Clin Exp Pharmacol Physiol; 2014 Feb; 41(2):118-26. PubMed ID: 24471407
[TBL] [Abstract][Full Text] [Related]
14. Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation.
Zhang JD; Liu J; Zhu SW; Fang Y; Wang B; Jia Q; Hao HF; Kao JY; He QH; Song LJ; Liu F; Zhu BL; Owyang C; Duan LP
Acta Pharmacol Sin; 2021 Nov; 42(11):1821-1833. PubMed ID: 33558654
[TBL] [Abstract][Full Text] [Related]
15. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
16. Imipramine improves visceral sensation and gut barrier in rat models of irritable bowel syndrome.
Nozu T; Miyagishi S; Ishioh M; Takakusaki K; Okumura T
Eur J Pharmacol; 2020 Nov; 887():173565. PubMed ID: 32946869
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of patchouli alcohol on stress-induced diarrhea-predominant irritable bowel syndrome.
Zhou TR; Huang JJ; Huang ZT; Cao HY; Tan B
World J Gastroenterol; 2018 Feb; 24(6):693-705. PubMed ID: 29456408
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
Chen C; Tao C; Liu Z; Lu M; Pan Q; Zheng L; Li Q; Song Z; Fichna J
Phytother Res; 2015 Nov; 29(11):1822-7. PubMed ID: 26400188
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota of Diarrhea-Predominant Irritable Bowel Syndrome Patients Causes Hepatic Inflammation of Germ-Free Rats and Berberine Reverses It Partially.
Jia Q; Zhang L; Zhang J; Pei F; Zhu S; Sun Q; Duan L
Biomed Res Int; 2019; 2019():4530203. PubMed ID: 31073525
[TBL] [Abstract][Full Text] [Related]
20. Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome.
Sałaga M; Kowalczuk A; Zielinska M; Błażewicz A; Fichna J
Naunyn Schmiedebergs Arch Pharmacol; 2015 Oct; 388(10):1069-77. PubMed ID: 26068703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
